Welcome to our dedicated page for VIVO news (Ticker: VIVO), a resource for investors and traders seeking the latest updates and insights on VIVO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VIVO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VIVO's position in the market.
Meridian Bioscience, Inc. (NASDAQ: VIVO) has applied for Emergency Use Authorization (EUA) from the FDA for its SARS-CoV-2 molecular diagnostic test on the Revogene® platform. This test offers qualitative detection of the virus responsible for COVID-19 with results available in as little as 47 minutes, enhancing testing capacity for healthcare providers. This marks a milestone for the Revogene platform and supports the company’s strategy to expand its respiratory diagnostics. The test is yet to receive FDA clearance or approval.
Meridian Bioscience, a global leader in diagnostic testing solutions (NASDAQ: VIVO), has launched an innovative Air-Dryable RT-qPCR Mix. This cost-effective product allows molecular assays to be developed at ambient temperature, eliminating cold chain requirements. The new mix simplifies the manufacturing process, ensuring quick RNA target detection, making it ideal for COVID-19 assay development. It integrates all essential reagents within a one-tube format, facilitating ease of use across various testing platforms. This development positions Meridian as a key provider in the rapidly evolving molecular diagnostics industry.
Meridian Bioscience, Inc. (NASDAQ: VIVO) participated in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded fireside chat featuring CEO Jack Kenny and CFO Bryan Baldasare was held on November 17, 2020. Investors can register for access to this chat via the Company's Investor Relations website, with recordings available until February 15, 2021. Meridian develops and distributes innovative diagnostic products for various applications, focusing on delivering accurate and rapid solutions in healthcare diagnostics globally.
Meridian Bioscience, Inc. (NASDAQ: VIVO) will host a live stream fireside chat featuring CEO Jack Kenny and CFO Bryan Baldasare at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 12:30 PM ET. Investors can access the stream via the Company’s Investor Relations website. A recording will be available for one year post-event. Meridian is a life science company focused on innovative diagnostic products and provides crucial life science materials for various applications across over 70 countries.
Meridian Bioscience reported a 26% increase in consolidated net revenue for Q4 2020, totaling $64.2 million, and a record annual revenue of $253.7 million, attributed largely to its Life Science segment's growth of 106%.
However, the Diagnostics segment faced an 11% revenue decline year-over-year, despite a 38% rebound from Q3 FY20. The company anticipates continued strong performance in fiscal 2021, projecting revenues between $290 million and $310 million and adjusted earnings per share of $1.14 to $1.28.
Meridian Bioscience, Inc. (NASDAQ: VIVO) will announce its fourth quarter and full year 2020 financial results on November 13, 2020. CEO Jack Kenny and CFO Bryan Baldasare will lead a conference call at 10:00 a.m. ET to discuss the financial performance and answer questions. Participants can join the call via phone, with replay options available for 14 days after the event. Meridian is a comprehensive life science firm providing diagnostic and life science solutions globally, serving diverse sectors including healthcare and research.
Meridian Bioscience (NASDAQ: VIVO) has launched an innovative solution for cancer diagnostic tests, enhancing the detection of RNA and DNA from liquid biopsy samples, including whole blood. This approach offers a non-invasive alternative to traditional tissue biopsies. The company introduced two new inhibitor-resistant qPCR chemistries, allowing for sensitive assays without the need for nucleic acid extraction. These tools promise faster turnaround times and improved detection capabilities, addressing challenges in cancer biomarker detection.
Meridian Bioscience (NASDAQ: VIVO) has launched a novel SARS-CoV-2 antibody pair targeting the trimeric spike protein, aimed at enhancing COVID-19 assay development from patient saliva. This highly sensitive antibody pair operates down to picograms per milliliter, specifically binding to the SARS-CoV-2 spike protein without cross-reacting with other coronaviruses. The company is committed to accelerating the scale-up of these antibodies for rapid antigen testing, reinforcing its position as a key partner in the diagnostics industry during the pandemic.
Meridian Bioscience (NASDAQ: VIVO) will present at the H. C. Wainright 22nd Annual Global Investment Conference on September 14, 2020, at 12:30 PM ET. Jack Kenny, CEO, and Bryan Baldasare, CFO, will lead the presentation. Interested participants can access the live webcast through the Company’s Investor Relations website. Meridian Bioscience specializes in innovative diagnostic products and serves customers in over 70 countries, focusing on areas like gastrointestinal infections and blood lead level testing.
Meridian Bioscience announced a record net revenue of $84.8 million for Q3 FY2020, marking a 75% increase year-over-year. The Life Science segment thrived with revenues up 312% to $63.2 million, driven by strong demand for COVID-19 products, contributing $47.8 million to this segment. However, the Diagnostics segment saw a 35% decline in revenue, totaling $21.6 million. The company is raising its FY2020 revenue guidance to $245-$250 million. GAAP earnings per share were reported at $0.64, with an adjusted EPS of $0.55.
FAQ
What is the market cap of VIVO (VIVO)?
